Vugene
Founded 2021 · 25 employees on LinkedIn · 4 known investors
VUGENE offers an AI/ML-powered multi-omics analysis platform that turns raw biological data—genomics, transcriptomics, proteomics, metabolomics, epigenomics, and single-cell data—into actionable insights on how drugs affect biology. It serves principal investigators, research institutions, biotech and pharmaceutical companies, hospitals, and contract research organizations for target identification, mechanism-of-action, and translational research.
Also known as VUGENE · VUGENE, LLC · VUGENE, UAB
Founders & leadership
Vugene was founded in 2021 by Juozas Gordevičius.
Investors · 4
Also in the syndicate · 2
Funding
SEC filings, press & company announcements- Undisclosed amountprivate financing roundMay 2025
Superhero Capital (lead), Coinvest Capital, NGL Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026VUGENE is a biomedical data science company that analyses and interprets multi-omics data for life science research and drug development. Its platform covers genomics, transcriptomics, epigenomics, metabolomics, proteomics and single-cell and spatial approaches, and integrates data across these layers to support target identification, mechanism-of-action studies, biomarker discovery and translational research. The company positions its output as AI-powered insights on what a drug does to biology delivered in days rather than months or years, with results provided as interactive web applications that can be explored and shared among stakeholders.
Alongside software-based analysis, VUGENE offers statistical modelling, pathway analysis, comparative studies and expert scientific guidance on study design and interpretation. It describes itself as a "Service-as-a-Software" company and employs a multidisciplinary team of bioinformaticians, scientists and engineers. Leadership includes Gražina Mykolaitytė-Nielsen (CEO and co-founder), Juozas Gordevičius (founder and CSO), Ramūnas Markauskas (CTO) and Edita Karosienė (Head of Science).
Founding story
The company was founded in 2021 by Juozas Gordevičius with the stated mission of bringing together experts in biology, data analysis and computer science to transform and advance health-related scientific research. Gordevičius holds a PhD in Computer Science from the Free University of Bozen-Bolzano and previously conducted biomedical research at UCLA, the University of Toronto and the Van Andel Research Institute, focusing on the epigenetics of aging and complex diseases.
Business model
VUGENE describes itself as a Service-as-a-Software company: it combines an AI/ML multi-omics analysis platform with expert bioinformatics and scientific advisory services delivered to research and industry customers, and is investing in platform automation to move from a service-provider model toward a product-focused enterprise.
Traction
The company reports more than 6,500 completed studies, over 170,000 samples processed, more than 25 TB of datasets and over 30 enterprise clients. As of May 2025 it had 13 employees, with roughly 85% of its client base in the United States, and named research and clinical institutions among its customers.
Latest developments
In May 2025 VUGENE closed a €1 million ($1.1 million) round led by Superhero Capital with NGL Ventures, Coinvest Capital and angel investors. The company stated it was targeting a potential $10 million Series A by the end of the year, focused on US-based investors. Recent published materials cover single-cell and spatial transcriptomics analysis and the gap between multi-omics data generation and mechanistic interpretation in drug development.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
VUGENE presents itself as addressing the gap between the volume of multi-omics data generated and mechanistic decision-making in drug development. Investors in its 2025 round described it as automating complex biological data interpretation in a market the company sized at a potential USD 16 billion opportunity.
Technology
The platform uses artificial intelligence and machine learning to identify patterns and candidate biomarkers in complex biological datasets, supports cross-study and cross-platform integration including comparisons across models and organisms, and applies statistical modelling and pathway analysis across genomics, transcriptomics, epigenomics, metabolomics, proteomics and bulk, single-cell and spatial methods. Analysis of single-cell and spatial transcriptomics studies is automated step by step, with results delivered as interactive web applications.
Go-to-market
Customers engage via demo requests and direct inquiry through the company website and scheduled calls. Growth to date has come from academic research users expanding into industry accounts; proceeds from the 2025 round were earmarked for team expansion, particularly sales roles across the US and Europe, and for platform automation.
Individual principal investigators, research institutions, biotech and pharmaceutical companies, bioinformaticians, hospitals and contract research organizations. Named clients include Corewell Health, Barrow Neurological Institute, the Epigenetic Clock Development Foundation, RUSH University Medical Center, rAAVen Therapeutics and Biocrates.
Geography
Headquarters and operations in Lithuania, with offices in Vilnius (Antakalnio st. 17) and Kaunas (K. Donelaičio st. 62), plus a US entity, VUGENE, LLC, with an address in Grand Rapids, Michigan and a legal entity established in Delaware. A chief scientific officer operates from Cambridge, UK. Approximately 85% of clients are US-based.
History
VUGENE was founded in 2021 by Juozas Gordevičius. The team grew from five to 13 employees over the two years preceding May 2025. Initial adoption came from academic research and later expanded into industry. In May 2025 the company closed its first external investment round, €1 million led by Superhero Capital, and had established a US legal entity in Delaware alongside its Lithuanian operations.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsVUGENE announced the closing of a €1 million round led by Superhero Capital with participation from NGL Ventures, Coinvest Capital and angel investors, to be deployed toward becoming a global service-as-a-software company, team expansion in US and European sales roles, and platform automation. It was the company's first investment round.
$1.1M source ↗
VUGENE lists partnerships with The Clock Foundation (epigenetic aging clocks for preclinical and clinical studies), Biocrates (mass spectrometry-based metabolomics kits and services) and Inotiv, Inc. (contract research organization for nonclinical and analytical drug discovery and development services).
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 7
primary sources listed
- Vugenevugene.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Vugene do?
- VUGENE is a Lithuania-based biomedical data science company applying AI/ML to multi-omics data analysis and interpretation.
- Who founded Vugene?
- Vugene was founded by Juozas Gordevičius in 2021.
- Who are Vugene's investors?
- Vugene's investors include Superhero Capital, Coinvest Capital.